Cystic Fibrosis – a Multiorgan Protein Misfolding Disease

References

• Dodge JA , LewisPA, StantonM, WilsherJ. Cystic fibrosis mortality and survival in the UK: 1947–2003. Eur. Resp. J.29, 522–526 (2007).
   PubMed Web of Science ®Google Scholar
• Goetzinger KR , CahillAG. An update on cystic fibrosis screening. Clin. Lab. Med.30(3), 533–543 (2010).
   PubMed Web of Science ®Google Scholar
• Xu Y , SzépS, LuZ. The antioxidant role of thiocyanate in the pathogenesis of cystic fibrosis and other inflammation-related diseases. Proc. Natl Acad. Sci. USA106(48), 20515–20519 (2009).
   PubMed Web of Science ®Google Scholar
• Kerem B , RommensJM, BuchananJAet al. Science 245, 1073–1080 (1989).
   PubMed Web of Science ®Google Scholar
• Ward CL , OmuraS, KopitoRR. Degradation of CFTR by the ubiquitin-proteasome pathway. Cell83(1), 121–127 (1995).
   PubMed Web of Science ®Google Scholar
• Thrower JS , HoffmanL, RechsteinerM, PickartCM. Recognition of the polyubiquitin proteolytic signal. EMBO J.19(1), 94–102 (2000).
   PubMed Web of Science ®Google Scholar
• Rogan MP , StoltzDA, HornickDB. Cystic fibrosis transmembrane conductance regulator intracellular processing, trafficking and opportunities for mutation-specific treatment. Chest139, 1480–1490 (2011).
   PubMed Web of Science ®Google Scholar
• Schloesser M , ArlethS, LenzU, BerteleRM, ReissJ. A cystic fibrosis patient with the nonsense mutation G542X and the splice site mutation 1717–1. J. Med. Genet.28, 878–880 (1991).
   PubMed Web of Science ®Google Scholar
• Bompadre SG , SohmaY, LiM. G551D and G1349D, two CF-associated mutations in the signature sequences of CFTR exhibit distinct gating defects. J. Gen. Physiol.129, 285–298 (2007).
   PubMed Web of Science ®Google Scholar
• Flume PA , O’SullivanBP, RobinsonKAet al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am. J. Respir. Crit. Care Med.176(10), 957–969 (2007).
   PubMed Web of Science ®Google Scholar
• Bobadilla JL , MacekM, FineJP, FarrellPM. Cystic fibrosis: a worldwide analysis of CFTR mutations – correlation with incidence data and application to screening. Hum. Mutat.19, 575–606 (2002).
   PubMed Web of Science ®Google Scholar
• Accurso FJ , RoweSM, ClancyJPet al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N. Engl. J. Med.363(21), 1991–2003 (2010).
   PubMed Web of Science ®Google Scholar
• Eckford PD , LiC, RamjeesinghM, BearCE. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation, but ATP-independent manner. J. Biol. Chem.287(44), 36639–36649 (2012).
   PubMed Web of Science ®Google Scholar
• Ren HY , GroveDE, De La RosaOet al. VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1. Mol. Biol. Cell24(19), 3016–24 (2013).
   PubMed Web of Science ®Google Scholar
• Van Goor F , HadidaS, GrootenhuisPDJet al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc. Natl Acad. Sci. USA108(46), 18843–18848 (2011).
   PubMed Web of Science ®Google Scholar
• Clancy JP , RoweSM, AccursoFJet al. Results of a Phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax67(1), 12–18 (2012).
   PubMed Web of Science ®Google Scholar
• Ellen WM , BartonER, ZhuoJet al. PTC124 targets genetic disorders caused by nonsense mutations. Nature447, 87–91 (2007).
   PubMed Web of Science ®Google Scholar
• Peltz SW , MorsyM, WelchEM, JacobsonA. Ataluren as an agent for therapeutic nonsense suppression. Annu. Rev. Med.64, 407–425 (2013).
   PubMed Web of Science ®Google Scholar
• Chandler JD , MinE, HuangJ, NicholsDP, DayBJ. Nebulized thiocyanate improves lung infection outcomes in mice. Br. J. Pharmacol.169(5), 1166–1177 (2013).
   PubMed Web of Science ®Google Scholar
• Hopkins N , GunningY, O’CroininDF, LaffeyJG, McLoughlinP. Anti-inflammatory effect of augmented nitric oxide production in chronic lung infection. J. Pathol.209(2), 198–205 (2006).
   PubMed Web of Science ®Google Scholar
• Miller CC , HergottCA, RohanM, Arsenault-MehtaK, DöringG, MehtaS. Inhaled nitric oxide decreases the bacterial load in a rat model of Pseudomonas aeruginosa pneumonia. J. Cyst. Fibros.12(6), 817–820 (2013).
   PubMed Web of Science ®Google Scholar
• Grasemann H , GrasemannC, KurtzF, Tietze-SchillingsG, VesterU, RatjenF. Oral L-arginine supplementation in cystic fibrosis patients: a placebo-controlled study. Eur. Respir. J.25(1), 62–68 (2005).
   PubMed Web of Science ®Google Scholar
• Grasemann H , TullisE, RatjenF. A randomized controlled trial of inhaled L-arginine in patients with cystic fibrosis. J. Cyst. Fibros.12(5), 468–474 (2013).
   PubMed Web of Science ®Google Scholar
• Michl RK , HentschelJ, FischerC, BeckJF, MainzJG. Reduced nasal nitric oxide production in cystic fibrosis patients with elevated systemic inflammation markers. PLoS ONE8(11), e79141 (2013).
   PubMed Web of Science ®Google Scholar
• Walker WT , LiewA, HarrisA, ColeJ, LucasJS. Upper and lower airway nitric oxide levels in primary ciliary dyskinesia, cystic fibrosis and asthma. Respir. Med.107(3), 380–386 (2013).
   PubMed Web of Science ®Google Scholar
• Luciani A , VillellaVR, EspositoSet al. Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition. Nat. Cell Biol.12(9), 863–875 (2010).
   PubMed Web of Science ®Google Scholar
• Lee TW , SouthernKW. Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease. Cochrane Database Syst. Rev.11, CD005599 (2013).
   Google Scholar
• Griesenbach U , AltonEW. Moving forward: cystic fibrosis gene therapy. Hum. Mol. Genet.22(R1), R52–R58 (2013).
   PubMedGoogle Scholar
• Schwank G , KooBK, SassalliVet al. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell.13(6), 653–658 (2013).
   PubMed Web of Science ®Google Scholar
• Fanen P , Wohlhuter-HaddadA, HinzpeterA. Genetics of cystic fibrosis: CFTR mutation classifications toward genotype-based CF therapies. Int. J. Biochem. Cell. Biol.52, 94–102 (2014).
   PubMed Web of Science ®Google Scholar
• Wainwright CE , ElbornJS, RamseyBWet al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N. Engl. J. Med.373(3), 220–221 (2015).
   PubMed Web of Science ®Google Scholar
• Stephens D , GareyN, IslesA, LevisonH, GoldR. Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis. Pediatr. Infect. Dis.2(3), 209–11 (1983).
   PubMedGoogle Scholar
• Jensen T , PedersenSS, GarneS, HeilmannC, H⊘ibyN, KochC. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J. Antimicrob. Chemother.19(6), 831–838 (1987).
   PubMed Web of Science ®Google Scholar
• Ryan G , SinghM, DwanK. Inhaled antibiotics for long term therapy in cystic fibrosis. Cochrane Database Syst Rev.3, CD001021 (2011).
   PubMed Web of Science ®Google Scholar
• The Review on Antimicrobial Resistance . Securing new drugs for future generations: the pipeline of antibiotics (2015). http://amr-review.org/sites/default/files/SECURING%20NEW%20DRUGS%20FOR%20FUTURE%20GENERATIONS%20FINAL%20WEB_0.pdf
   Google Scholar
• Trapnell BC , McColleySA, KissnerDGet al. Phase 2 FTI Study Group. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection. Am. J. Respir. Crit. Care Med.185(2), 171–178 (2012).
   PubMed Web of Science ®Google Scholar
• Yang Y , TsifanskyMD, WuCJ, YangHI, SchmidtG, YeoY. Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis. Pharm. Res.27(1), 151–160 (2010).
   PubMed Web of Science ®Google Scholar
• Charrier C , RodgerC, RobertsonJet al. Cysteamine (Lynovex®), a novel mucoactive antimicrobial & antibiofilm agent for the treatment of cystic fibrosis. Orphanet. J. Rare Dis.9, 189 (2014).
   PubMed Web of Science ®Google Scholar
• Gibson RL , Retsch-BogartGZ, OermannCet al. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr. Pulmonol.41(7), 656–65 (2006).
   PubMed Web of Science ®Google Scholar
• Stockmann C , HillyardB, AmpofoK, SpigarelliMG, SherwinCM. Levofloxacin inhalation solution for the treatment of chronic Pseudomonas aeruginosa infection among patients with cystic fibrosis. Expert Rev. Respir. Med.9(1), 13–22 (2015).
   PubMed Web of Science ®Google Scholar
• Siekmeier R1 , HofmannT, ScheuchG. Inhalation of macrolides: a novel approach to treatment of pulmonary infections. Adv. Exp. Med. Biol.839, 13–24 (2015).
   PubMed Web of Science ®Google Scholar
• Cigana C , NicolisE, PasettoM, AssaelBM, MelottiP. Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells. Biochem. Biophys. Res. Commun.350(4), 977–82 (2006).
   PubMed Web of Science ®Google Scholar
• Skindersoe ME , AlhedeM, PhippsRet al. Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa. Antimicrob. Agents Chemother.52(10):3648–63 (2008).
   PubMed Web of Science ®Google Scholar
• Mulet X , MaciáMD, MenaA, JuanC, PérezJL, OliverA. Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. Antimicrob. Agents Chemother.53(4):1552–60 (2009).
   PubMed Web of Science ®Google Scholar
• Alton EW , ArmstrongDK, AshbyDet al. Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, Phase 2b trial. Lancet Respir Med. doi:10.1016/S2213-2600(15)00245-3 (2015) ( Epub ahead of print).
   PubMedGoogle Scholar